Prognostic and predictive value of an immune-related adverse event among stage III melanoma patients included in the EORTC 1325/KEYNOTE-054 pembrolizumab versus placebo trial.
Year: 2019
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Alexander M. M. Eggermont, Michal Kicinski, Christian U. Blank, Mario Mandalà, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Mark Haydon, Mikhail Lichinitser, Muhammad Khattak, Matteo S. Carlino, Shahneen Kaur Sandhu, Susana Puig, Paolo Antonio Ascierto, Clemens Krepler, Nageatte Ibrahim, Sandrine Marreaud, Alexander Christopher Jonathan Van Akkooi, Caroline Robert, Stefan Suciu
Institutions: Université Paris-Saclay, European Organisation for Research and Treatment of Cancer, The Netherlands Cancer Institute, Ospedale Papa Giovanni XXIII, The University of Sydney, Melanoma Institute Australia, The University of Queensland, Hospices Civils de Lyon, The Alfred Hospital, Russian Cancer Research Center NN Blokhin, The University of Western Australia, Fiona Stanley Hospital, The University of Melbourne, Peter MacCallum Cancer Centre, Hospital Clínic de Barcelona, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Merck & Co., Inc., Rahway, NJ, USA (United States), Institut Gustave Roussy
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2947435541